Cargando…
Therapeutic Role of Pharmacological Chaperones in Lysosomal Storage Disorders: A Review of the Evidence and Informed Approach to Reclassification
The treatment landscape for lysosomal storage disorders (LSDs) is rapidly evolving. An increase in the number of preclinical and clinical studies in the last decade has demonstrated that pharmacological chaperones are a feasible alternative to enzyme replacement therapy (ERT) for individuals with LS...
Autores principales: | Keyzor, Ian, Shohet, Simon, Castelli, Jeff, Sitaraman, Sheela, Veleva-Rotse, Biliana, Weimer, Jill M., Fox, Brian, Willer, Tobias, Tuske, Steve, Crathorne, Louise, Belzar, Klara J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10452329/ https://www.ncbi.nlm.nih.gov/pubmed/37627292 http://dx.doi.org/10.3390/biom13081227 |
Ejemplares similares
-
Brain patterning perturbations following PTEN loss
por: Veleva-Rotse, Biliana O., et al.
Publicado: (2014) -
Treating lysosomal storage diseases with pharmacological chaperones: from concept to clinics
por: Parenti, Giancarlo
Publicado: (2009) -
Expression of myeloid differentiation factor 88 in neurons is not requisite for the induction of sickness behavior by interleukin-1β
por: Braun, Theodore P, et al.
Publicado: (2012) -
Impairment of chaperone-mediated autophagy leads to selective lysosomal degradation defects in the lysosomal storage disease cystinosis
por: Napolitano, Gennaro, et al.
Publicado: (2015) -
Tuning protein folding in lysosomal storage diseases: the chemistry behind pharmacological chaperones
por: Pereira, David M., et al.
Publicado: (2018)